Vedanta Biosciences

Vedanta Biosciences is a biotechnology company focused on developing a new class of drugs to treat gastrointestinal diseases through microbiome modulation. The company has pioneered the discovery of commensal gut bacteria that play a role in immune regulation and immune potentiation. Vedanta offers a product engine that enables the identification of bacteria with drug-like properties and their assembly into rationally-designed consortia for optimal therapeutic activity. The company has achieved commercial-scale CGMP production of drug candidates based on defined bacterial consortia and holds foundational intellectual property covering bacterial consortia drugs containing Clostridium organisms. Vedanta’s pipeline includes product candidates such as VE303 for recurrent C. difficile infection and VE202 for inflammatory bowel disease. The company has received $106 million in funding for Phase III trials in C. difficile infection and Phase II trials in inflammatory bowel disease, backed by Pfizer. Additionally, Vedanta has unveiled a state-of-the-art, multi-product CGMP manufacturing facility to support clinical trials and the potential commercial launch of VE303.